017.2 WOMEN'S EXPERIENCES WITH PRIMARY HUMAN PAPILLOMAVIRUS (HPV) TESTING FOR CERVIX SCREENING: HPV FOCAL EXIT SURVEY RESULTS

¹Laurie Smith*, ¹Dirk Van Niekerk, ²Mel Krajden, ¹Lovedeep Gondara, ²Darrel Cook, ¹Marette Lee, ³Ruth Martin, ³Gavin Stuart, ⁴Stuart Peacock, ⁵Eduardo Franco, ⁴Andrew Coldman, ³Gina Ogilvie. ¹BC Cancer, Vancouver, Canada; ²BC Centre for Disease Control, Vancouver, Canada; ³University of British Columbia, Vancouver, Canada; ⁴BC Cancer Research Centre, Vancouver, Canada; ⁵McGill University, Montreal, Canada

10.1136/sextrans-2019-sti.200

Background Globally, cervical screening is moving from cytology (Pap) to HPV-based testing. Cytology-based screening has occurred for decades; therefore, engaging the screened population is critical to success of this significant paradigm shift. HPV FOCAL, a large clinical trial, compared primary HPV testing every 4 years to liquid-based cytology (LBC) every 2 years. Participants were surveyed to assess experiences surrounding HPV screening.

Methods Women aged 25–65 (n=19,009) from two urban centres were randomized to control (LBC) or intervention (HPV) arms, and 16,374 women attended 48 month exit with HPV/LBC co-testing. At trial entry, women were provided information about HPV, cervical cancer, HPV testing and results. Women completing exit screening were invited to complete a survey assessing attitudes to HPV vs. Pap testing, screening intervals, and receipt of HPV results.

Results Of 14,535 invites sent, 5,532 (38%) responders completed some or all of the survey with 63% reporting that HPV vs. Pap testing was acceptable; and 54% willing to have HPV testing every 4–5 yrs vs. a Pap every 3 yrs. Concerns regarding HPV positive results differed by age. More women ≥50 yrs reported it important for them to know who gave them HPV than younger women (25–34 yrs: 68%; 35–49 yrs: 69%; 50+ yrs: 76%). More women 25–34 yrs than >35 yrs would feel judged for having HPV (25–34 yrs: 44%; 35–49 yrs: 36%; 50+ yrs: 34%). More women ≥50 yrs reported being HPV positive would affect the relationship with a sexual partner (25–34 yrs: 36%; 35–49 yrs: 41%; 50+: 45%). Response differences by education will also be presented.

Conclusion In this large HPV screening trial, the majority of women reported that HPV vs. Pap testing was acceptable and over half would be willing to have HPV testing every 4–5 yrs. Women had varied concerns regarding HPV positive results and responses varied by age. These findings illustrate the importance of comprehensive, targeted communication strategies prior to implementation of primary HPV screening.

Disclosure No significant relationships.

017.3 DECLINING RATES OF CERVICAL INTRAEPITHELIAL NEOPLASIA AFTER INTRODUCTION OF THE HPV VACCINE IN BRITISH COLUMBIA, CANADA

¹Robine Donken*, ²Dirk Van Niekerk, ²Jeremy Hamm, ²Laurie Smith, ³Manish Sadarangani, ⁴Monika Naus, ⁵Deborah Money, ⁶Simon Dobson, ⁴Dianne Miller, ⁷Mel Krajden, ²Marette Lee, ⁸Sheona Mitchell-Foster, ²John Spinelli, ⁹Andrew Coldman, ⁵Gina Ogilvie. ¹BC Children's Research Institute, Vaccine Evaluation Center, Vancouver, Canada; ²BC Cancer, Vancouver, Canada; ³BC Children's Hospital Research Institute, Vaccine Evaluation Center, Vancouver, Canada; ⁴University of British Columbia, Faculty of Medicine, Vancouver, Canada; ⁵University of British Columbia, Vancouver, Canada; ⁶Sidra Medicine, Doha, Qatar; ⁷BC CDC, Vancouver, Canada; ⁸University of Northern British Columbia, Northern Medical Program, Prince George, Canada; ⁹BC Cancer Research Centre, Vancouver, Canada

10.1136/sextrans-2019-sti.201

Background In 2008 British Columbia (BC), Canada, implemented a voluntary school-based HPV vaccination program for girls, born 1994 or later, with an average uptake of 63%. Given the long time-lead between infection and malignant disease, effects on cancer incidence will take decades to assess. To evaluate the early impact of the HPV vaccine in BC, ecological trends in cervical intraepithelial neoplasia (CIN) rates were assessed in young women before and after the implementation of the HPV vaccination program.

Methods From the population-based cervical cancer screening program database in BC, information on all Pap smears and histopathological abnormalities, in calendar years 2004–2017 in women under age 28 were obtained. Rates of cervical intraepithelial neoplasia (CIN) were calculated as the number of cases divided by the number of cytology specimens for that period. Incidence rate ratios (IRR) comparing pre- and post-vaccination years, adjusted for age and screening year, were calculated by piece-wise Poisson regression analysis. We performed a sensitivity analysis including only women eligible for routine screening.

Results The total number of screens in the unvaccinated cohort was 1,417,512 and in the vaccinated cohort 73,343. After the introduction of the HPV vaccination program in BC, a decrease in the incidence of CIN was observed in vaccine-eligible birth cohorts. The adjusted IRR for CIN1, 2 and 3 were respectively 0.60 (95%CI 0.53–0.67), 0.49 (95%CI 0.41–0.57) and 0.39 (95%CI 0.32–0.47). Sensitivity analysis confirmed these findings, also indicating a significant decline in CIN rates in birth cohorts eligible for the HPV vaccination program.

Conclusion This study illustrates the population impact of the provincial school-based HPV vaccination program, by an observed decline in rates of CIN since introduction of the program. Further evaluation of the population-based impact includes a linkage between vaccination and screening registry.

Disclosure No significant relationships.

017.4 IMPACT OF THE HUMAN PAPILLOMAVIRUS IMMUNIZATION PROGRAM ON RATES OF ANOGENITAL WARTS IN BRITISH COLUMBIA, CANADA 2000–2017

¹Christine Lukac*, ²Robine Donken, ³Michael Otterstatter, ⁴Olga Mazo, ⁴Stanley Wong, ⁵Fawziah Marra, ⁶Laurie Smith, ⁷Monika Naus, ¹Deborah Money, ⁸Mel Krajden, ⁴Troy Grennan, ⁴Mark Gilbert, ⁴Jason Wong, ⁹Gina Ogilvie. ¹University of British Columbia, Faculty of Medicine, Vancouver, Canada; ²BC Children's Research Institute, Vaccine Evaluation Center, Vancouver, Canada; ³BC Centre for Disease Control, Vancouver, Canada; ⁴BC Centre for Disease Control, Clinical Prevention Services, Vancouver, Canada; ⁵University of British Columbia, Faculty of Pharmacy, Vancouver, Canada; ⁶BC Cancer, Vancouver, Canada; ⁷BC Centre for Disease Control, Communicable Diseases and Immunization Service, Vancouver, Canada; ⁸BC Centre for Disease Control, Public Health Laboratory, Vancouver, Canada; ⁹BC Women's Hospital, Women's Health Research Institute, Vancouver, Canada

10.1136/sextrans-2019-sti.202

Background In 2008, British Columbia (BC), Canada, implemented a provincially-funded school-based quadrivalent human papillomavirus (HPV-4) vaccine program for girls born in 1994 or later. In 2015, the program was expanded to include men who have sex with men (MSM) born in 1989 or later. To determine the impact of the vaccine on anogenital warts (AGW), diagnosis rates were measured among women who have sex with men (WSM), men who have sex with women (MSW), and MSM.